Activation of TGF-β activated kinase 1 promotes colon mucosal pathogenesis in inflammatory bowel disease

Zhiwei Liu1,3, Fansheng Kong1, Jefferson E. Vallance2, Eleana Harmel-Laws2, Surya Amarachintha2, Kris A. Steinbrecher2, Michael J. Rosen2 & Sandip Bhattacharyya1

1 Department of Pediatrics, Center for Prevention of Preterm Birth, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati Ohio
2 Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, College of Medicine, Cincinnati, Ohio

Keywords
Glucocorticoid, intestinal inflammation, TAK1.

Correspondence
Sandip Bhattacharyya, Cincinnati Children’s Hospital, 3333 Burnet Avenue, Room 4447, Cincinnati, OH45229.
Tel: 513 803 8039
Fax: 513 803 5009
E-mail: Sandip.Bhattacharyya@cchmc.org

Present address
Zhiwei Liu, Neonatal Division, International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Minhang Qu, China

Funding Information
This work was supported primarily by the Center for Prevention of Preterm Birth, Cincinnati Children’s Hospital Medical Center. Studies were also supported in part by Pilot and Feasibility Award, Digestive Health Center: Bench to Bedside Research in Pediatric Digestive Disease, under award number P30 DK078392 (to S.B.).

Received: 25 September 2016; Revised: 30 January 2017; Accepted: 3 February 2017
doi: 10.14814/phy2.13181

Abstract
The etiology and mechanisms for inflammatory bowel disease (IBD) are incompletely known. Determination of new, clinically important mechanisms for intestinal inflammation is imperative for developing effective therapies to treat IBD. We sought to define a widespread mechanism for colon mucosal inflammation via the activation of TGF-β activated Kinase 1 (TAK1), a central regulator of cellular inflammatory actions. Activation of TAK1 and the downstream inflammatory signaling mediators was determined in pediatric patients with ulcerative colitis (UC) or Crohn’s disease (CD) as well as in DSS-induced and spontaneous IBD in mice. The role of TAK1 in facilitating intestinal inflammation in murine models of IBD was investigated by using (5Z)-7-Oxo-zeaenol, a highly selective pharmacological inhibitor of TAK1. We found hyper-activation of TAK1 in patients with UC or CD and in murine models of IBD. Pharmacological inhibition of TAK1 prevented loss in body weight, disease activity, microscopic histopathology, infiltration of inflammatory cells in the colon mucosa, and elevated proinflammatory cytokine production in two murine models of IBD. We demonstrated that at the early phase of the disease activation of TAK1 is restricted in the epithelial cells. However, at a more advanced stage of the disease, TAK1 activation predominantly occurs in nonepithelial cells, especially in macrophages. These findings elucidate the activation of TAK1 as crucial in promoting intestinal inflammation. Thus, the TAK1 activation pathway may represent a suitable target to design new therapies for treating IBD in humans.

Introduction
Patients suffering from IBD exhibit chronic intestinal inflammation due to dysregulated mucosal immune response and epithelial barrier disruption (Xavier and Podolsky 2007). Despite many years of extensive research indicating a complex interplay of genetic, microbial, and environmental contributions as possible
TAK1 Activation in IBD

Z. Liu et al.

Factors associated with aberrant intestinal inflammation, the etiology and mechanisms for disease pathogenesis remain elusive (Xavier and Podolsky 2007). Hence, currently available therapies for pediatric IBD frequently fail to resolve inflammation (Kozuch and Hanauer 2008). For example, 50% of the patients that undergo glucocorticoid (GC) therapy develop steroid-dependency or require surgery (Accituno et al. 2008); 20–30% of patients are GC nonresponders (Rosen et al. 2015). Anti-TNF therapy, so far the best treatment for moderate-to-severe IBD, promotes mucosal healing in only 30–50% of the patients (Colombel et al. 2010, 2011). Defining new, clinically relevant mechanisms for intestinal inflammation is a clear need for developing efficient therapies in IBD.

Targeting of signaling mediators of inflammatory pathways, such as MAP kinases (MAPKs) and JAK-STAT is an emerging field in developing therapies in IBD (Van Den Blink et al. 2002; Bamias et al. 2016). Activation of TGF-β activated Kinase 1 (TAK1) is crucial in engaging multiple innate immune signaling pathways including NFκB, Activated Protein1 (AP1), MAPK, and STAT that promote inflammatory responses in IBD (Kawai and Akira 2006; Abbott et al. 2007; Adhikari et al. 2007). TAK1 is a serine/threonine kinase in the MAPK kinase kinase (MAP3K) family and is induced by a spectrum of stimuli (Sakurai 2012). Involvement of TAK1 in inflammatory ailments is well demonstrated (Ma et al. 2011; Neubert et al. 2011; Ridder et al. 2011; Ridder and Schwaninger 2012; Sakurai 2012). Activation of TAK1 promotes clinical complications in the digestive system. TAK1 is activated in colon cancer (Takahashi et al. 2015), and inhibition of TAK1 reduced colon tumor cell growth (Singh et al. 2012). Also, blocking TAK1 activation decreases chemoresistance in pancreatic cancer (Melisi et al. 2011).

The role of TAK1 in IBD is not clear. Deletion of TAK1 in T-cell–induced intestinal inflammation (Sato et al. 2006). The same group later found that in these mice TAK1 expression is retained in CD4+ T-cells. These cells acquire an inflammatory phenotype and continuous access to colon that result in pathogenesis in colitis (Sanjo et al. 2015). Also, TAK1 in epithelial cells was protective in mouse colitis (Kajino-Sakamoto et al. 2008; Kim et al. 2009). Enterocyte-specific constitutive deletion of TAK1 in mice developed spontaneous intestinal inflammation (Kajino-Sakamoto et al. 2008). TAK1 in intestinal epithelial cells exhibited cytoprotective roles in chemical (DSS)-induced colitis (Kim et al. 2009). The protective role of TAK1 is believed to be due to the maintenance of Paneth cell integrity via restraining necroptosis (Simmons et al. 2016). In contrast, phosphorylation/activation of TAK1 was increased in ileum from patients with CD and correlated with tissue fibrosis (Grillo et al. 2015). Also, TAK1 was activated in TNBS-induced colitis (Lim et al. 2015). Deletion of CYLD, a TAK1 deubiquitinating enzyme in T-cells resulted in TAK1 hyper-activation and spontaneous intestinal inflammation (Reiley et al. 2007). Raf kinase inhibitor protein (RKIP) promoted intestinal epithelial cell apoptosis in human and mouse IBD via interaction with TAK1 (Lin et al. 2016). Also, a recent GWAS study suggested association of TAB 2, a TAK1-binding protein with IBD (Liu et al. 2015). However, the functional role of TAK1 in mediating mucosal pathogenesis in IBD remains to be determined.

Here, we test the hypothesis that activation of TAK1 mediates intestinal inflammation and pathogenesis in IBD. We provide evidence for hyper-activation of TAK1 in pediatric patients with UC and CD, as well as in chemically induced and spontaneous murine IBD. We demonstrate that GC, a mainstay therapy for IBD, fails to suppress the activation of TAK1 and downstream signaling mediators that induce intestinal inflammation. Our comprehensive analyses, utilizing TAK1-specific pharmacological inhibition, provide a direct evidence for TAK1 involvement in promoting mucosal pathogenesis in two different mouse models of IBD. These results implicate activation of TAK1 as an important mechanism for intestinal inflammation. Our studies suggest that ineffective suppression of TAK1 activation may be responsible for the limited efficacy of the interventions presently available for treating IBD.

Materials and Methods

Materials

TAK1 inhibitors (5Z)-7-Oxoozeanol (EMD Millipore, Billerica, MA), Dexamethasone, Piroxicam (Sigma, St. Louis, MO) were purchased and reconstituted as per the manufacturer’s instructions. Antibodies used in this study were as follows: anti-actin (A 5060) (Sigma); anti-phospho-TAK1 (06-1425) (Millipore, Temecula, CA); anti-phospho-TAK1 (109404) (Abcam, Cambridge, MA); anti-TAK1 (5206, 4505), anti-phospho-SAPK/JNK (4814, 9242) (Cell Signaling Technology, Beverly, MA); anti-TAK1 (7162) (Santa Cruz Biotechnology, Santa Cruz, CA).

Mice

Male and female mice (Jackson Laboratories, Bar Harbor, ME) were group-housed at Cincinnati Children’s Hospital...
Medical Center (CCHMC) Animal Facility under controlled temperature (25°C) and photoperiods (12 h light and 12 h dark cycle). Mice used for the experimentation were of C57BL/6 background, 6–8 weeks old (18–22 g) and allowed unrestricted access to standard diet and tap water. For each group of experiments, mice were matched by age, sex, and body weight.

Human samples
Rectosigmoid biopsies were obtained from the Division of Gastroenterology, Cincinnati Children’s Hospital Medical Center (CCHMC). Male and female pediatric patients (ages 4–18 years) with CD or UC, and patients found not to have intestinal inflammation (non-IBD) were recruited under approved IRB protocol. Patients undergoing colonoscopy for other routine clinical indications were enrolled to obtain non-IBD controls. Patients with indeterminate IBD were excluded from these studies. Prospectively collected endoscopic biopsy tissues were snap frozen at endoscopy and stored at −80°C.

DSS model of colitis
Acute colitis was induced by feeding male and female mice with 3% DSS (wt/vol) (mol wt 36–50 kDa; MP Biomedicals, Solon, OH) dissolved in drinking water. Fresh DSS solution was prepared daily and fed ad libitum for 7 days (Okayasu et al. 1990). The bedding was changed weekly and dirty cage bedding was transferred between cages to ensure a homogenous microbial environment. For the recovery model of colitis, mice received 3% DSS for 5 days followed by unsupplemented normal drinking water for 2 weeks.

IL-10−/− model of IBD
In the preliminary studies, phosphorylation of TAK1 was assessed in IL-10−/− male and female mice (10–12 weeks old, C57BL/6 background). At this age, IBD was developed spontaneously (Kawachi et al. 2000). To synchronize the onset and accelerate the development of IBD, IL-10−/− male and female mice (6–8 weeks old) were administered 200 ppm piroxicam (NSAID) in chow for 9 days (Holgersen et al. 2014).

In vivo treatment with TAK1 inhibitor
TAK1 inhibitor (SZ)-7-Oxozaeanol (Oxo) was resuspended as a 10 mg/mL stock in DMSO. This was further diluted in peanut oil (Sigma) to yield a lower concentration of the drug stock in 10% DMSO (Kong et al. 2015). Mice were injected with various doses of (SZ)-7-Oxozaeanol intraperitoneally. Alternatively, 10% DMSO in peanut oil was delivered as a vehicle control.

Tissue and plasma sampling
Colonic tissue and plasma samples were collected at time points as illustrated in the relevant figures. At each time point, blood was collected by retro-orbital phlebotomy into heparinized capillary tubes, with the time from first handling the animal to completion of the bleeding not exceeding 30 sec. Blood was collected in tubes containing EDTA, and plasma was frozen and kept at −80°C. The intestines were excised and rinsed with ice-cold PBS. The colon was cut close to the ileocecal valve and rectum, and the length was measured. Sections (1 cm) of the distal and proximal colon were cut out and opened longitudinally, fixed in 4% formalin solution, and embedded in paraffin for histological analysis. The remaining part of the colon was weighed and frozen in liquid nitrogen for subsequent molecular analysis.

Evaluation of disease activity
Mice were observed twice daily for water/food consumption, weight, morbidity, stool consistency, and the presence of blood in feces and at the anus. The disease activity index (DAI) was calculated by assigning well-established and validated scores for parameters (Cooper et al. 1993).

Evaluation of histopathology
4 µm thick paraffin-embedded sections were subjected to H&E staining for histological analysis. Histological scores were blindly determined as per Obermeier et al. (1999).

Immunofluorescence
For immunofluorescence staining of phosphor-TAK1, 2 µm frozen colon sections were used. Sections were stained with rabbit monoclonal anti-TAK1 (ab109404; Abcam) followed by goat anti-rabbit-Alexa Fluor-488 (ab150077; Abcam). For the nuclear counterstaining, sections were stained with DAPI (Life Technologies).

Radioimmunoassay
Plasma concentrations of corticosterone were determined by radioimmunoassay from blood collected by retro-orbital phlebotomy as described previously (Boyle et al. 2005). The corticosterone assays were performed as per
the manufacturer’s instructions (MP Biomedicals, Orangeburg, NY).

**Cytokine measurement**

In the DSS model of IBD, colons from the colorectal junction to the anus were excised at the indicated time points. Preliminary experiments indicated higher levels of proinflammatory cytokines in the distal colon than other parts of colon. These findings were concordant with more severe histological changes in the distal colon compared with the other parts of colon (data not shown). Based on these results, the distal colon was selected for cytokine measurement. The distal colon (2 cm from the rectum) was excised and snap-frozen. Samples were thawed at room temperature, homogenized in ice-cold PBS containing protease inhibitor cocktails (Sigma). Tissue processing was performed with TissueLyserII (Qiagen, Valencia, CA). Tissue homogenates were centrifuged at 3000g for 10 min at 4°C. The supernatants were separated into aliquots and frozen at −80°C until analyses. In the IL-10−/− model of IBD, the whole colonic tissues were homogenized due to heterogeneous pathogenesis throughout the colon in this model. Concentrations of TNF-α, IL-6, and IL-12 in tissue homogenates samples were measured by enzyme-linked immunosorbent assay (ELISA) as per the manufacturer’s instructions (BD Biosciences PharMingen, San Diego, CA). Cytokine concentrations are expressed as picograms per 100 µg of colonic tissue.

**Immunoblot analysis**

Colon tissues were disrupted with TissueLyserII in lysis buffer (20 mmol/L Tris-HCl pH 7.5, 150 mmol/L NaCl, 2 mmol/L EDTA, 1% NP-40) containing protease and phosphatase inhibitor cocktails, and supernatants were collected. Samples were resolved as described previously (Bhattacharyya et al. 2010). Blots were stripped with Restore™ Western Blot Stripping Buffer (Thermo Scientific, Rockford, IL) and reprobed with different antibodies. Band intensities were quantified by densitometry analyses (Image J, NIH).

**Statistical analysis**

All experiments were replicated three times to assure the reproducibility of the observations. Data are expressed as the mean ± SEM. For experiments yielding continuous data in three or more groups, ANOVA was applied as a global test for differences in the primary outcome variable. Histopathological scoring, as an ordinal variable, was compared among groups using the nonparametric Kruskal–Wallis test. Pair-wise comparisons were made only when an overall effect was detected using the Student’s t test or Mann–Whitney U test followed by Hochberg procedure to adjust for multiple comparisons. Repeated-measures two-way ANOVA with Bonferroni correction was used to compare measurements of mouse weight over time among experimental groups. Statistical analyses were performed using Prism 6.0 h (GraphPad Software, La Jolla, CA).

**Ethical considerations**

All authors concur with the submission of the manuscript. The current work has not been submitted or published elsewhere. Pediatric patients were enrolled through protocols approved by the Institutional Review Boards at CCHMC (IRB 2013-4749). Animal studies were performed following recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The experimental protocols were approved by the Animal Care and Use Committee of CCHMC.

**Results**

**Activation of TAK1 and the downstream signaling mediators in pediatric IBD**

Initially, we examined whether TAK1 is activated in pediatric patients with active UC or CD. To address this, study subjects with moderate to severe UC or CD were recruited. Phosphorylation of TAK1 is considered as a hallmark for its activation. We assessed TAK1 phosphorylation in the rectal biopsy tissues from male and female patients with or without IBD. Patients found not to have intestinal inflammation (non-IBD) were considered as the control for these studies. Low levels of TAK1 phosphorylation were observed in most (7/8) of the non-IBD patients (Table 1). However, biopsies from UC (7/8) and CD (6/8) patients exhibited high levels of TAK1 phosphorylation (Table 1). Densitometric analysis of the immunoblots indicated 8.6 (P = 0.001) and 9.8 (P = 0.005)-fold increase in TAK1 phosphorylation in patients with UC and CD, respectively, compared to non-IBD patients (Fig. 1). Activity of TAK1 stimulates the downstream signaling mediators and transcription factors, such as JNK, p38 MAPK, and NFκB. Consistent with TAK1 activation, phosphorylation of JNK was upregulated in patients with IBD; more prominently in patients with CD (Fig. 1). All non-IBD patients (8/8) exhibited low levels of JNK phosphorylation. In contrast, all CD (8/8) and most of the UC (6/8) patients demonstrated high levels of JNK phosphorylation (Table 1). Also, all UC (8/8) and CD (8/8) patients revealed high-p38
MAPK phosphorylation (Fig. 1). Phosphorylation of IκBα is required for the recruitment and activation of NFκB. In non-IBD patients, IκBα phosphorylation was found to be very low (Fig. 1). Most of the UC (5/8) and CD (6/8) patients exhibited moderate IκBα phosphorylation (Table 1). Together, TAK1 as well as the signaling intermediates downstream to TAK1 that mediate inflammatory reactions were markedly activated in male and female patients with UC or CD.

**Activation of TAK1 and the downstream signaling mediators in mouse models of IBD**

To understand the role of TAK1 in mediating the pathogenesis in IBD, DSS-induced colitis in wild-type C57BL/6 mice and spontaneous IBD in IL-10−/− mice (C57BL/6 background) were used as surrogates for human IBD. Mice were treated with 3% DSS to induce acute colitis as demonstrated in Figure 2A. The semichronic model of DSS-colitis is validated by several independent studies (Melgar et al. 2005; Sha et al. 2013). In the absence of DSS, phosphorylation of TAK1, JNK, and p38 MAPK in the colonic tissues were either undetectable or very low (Fig. 2B). However, substantial increases in TAK1, JNK, and p38 MAPK phosphorylation were observed after DSS treatment for 5 days. Consequences of DSS treatment on the phosphorylation of inflammatory signaling mediators were more pronounced after 7 days of treatment, the time point known to have more severe intestinal inflammation. In the recovery/semichronic phase of the disease, phosphorylation of TAK1, JNK, and p38 MAPK were reduced, but still higher than control mice, which were not treated with DSS (Fig. 2B). The above experiments were performed with male mice. To examine whether the activation of TAK1 and downstream signaling mediators in DSS-induced colitis is sex-dependent, similar studies were performed with age-matched male and female mice. There was no significant difference in phosphorylation of TAK1, JNK, and p38 MAPK between male and female mice (Fig. 2C).

The experiments with IL-10−/− mice were performed with adult mice (10–12 weeks old) to ensure detectable intestinal inflammation. Phosphorylation of TAK1, JNK, p38, and IκBα was elevated in IL-10−/− mice compared to control IL-10+/+ mice (Fig. 2D). These results were further supported by immunofluorescence analyses indicating substantial increase in

| Groups       | Patient No. | p-TAK1 expression Low (%) | p-TAK1 expression High (%) | p-IκBα expression Low (%) | p-IκBα expression High (%) | p-JNK expression Low (%) | p-JNK expression High (%) | p-p38 expression Low (%) | p-p38 expression High (%) |
|--------------|-------------|---------------------------|-----------------------------|---------------------------|-----------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Healthy control | 8           | 7 (88)                    | 1 (12)                     | 8 (100)                  | 0 (0)                       | 8 (100)                  | 0 (0)                    | 6 (75)                   | 2 (25)                   |
| UC           | 8           | 1 (22)                    | 7 (88)                     | 3 (36)                   | 5 (64)                     | 2 (25)                   | 6 (75)                   | 0 (0)                    | 8 (100)                  |
| CD           | 8           | 2 (25)                    | 6 (75)                     | 2 (25)                   | 6 (75)                     | 0 (0)                    | 8 (100)                  | 0 (0)                    | 8 (100)                  |

Expression of phospho-TAK1, phospho-IκBα, phospho-JNK, phospho-p38MAPK were analyzed by immunoblot analysis. The low- and high-grade phosphorylation of the signaling proteins was determined empirically. The percentage within parentheses indicates the proportion of patients with high or low levels of the relevant phosphorylated protein.
phospho-TAK1$^+$ cells in IL-10$^{-/-}$ mice compared to IL-10$^{+/+}$ mice (Fig. 2E). The majority of phospho-TAK1$^+$ cells were nonepithelial cells. At the early phase of DSS-colitis, after 3 days of DSS treatment a marked enhancement of phospho-TAK1 abundance was observed predominantly in the epithelial cells (Fig. 2F). At this phase of the disease, minimal epithelial damage was detected. In contrast, in the
Pharmacological inhibition of TAK1 reduces pathogenesis in DSS-induced acute IBD

To examine whether inhibition of TAK1 activation rescues DSS-mediated pathogenesis, mice were treated with (5Z)-7-Oxozeanol (Oxo), a highly selective pharmacological inhibitor of TAK1 widely used for preclinical studies (Ninomiya-Tsuji et al. 2003; Winsinger and Barluenga 2007; Neubert et al. 2011; Singh et al. 2012). Another group of mice were treated with both Oxo and Dex to assess whether the combination therapy provide beneficial effects. As TAK1 contributes to both immune and non-immune cellular functions, we first determined the optimal Oxo dose that does not incur overt toxicity. For these studies, mice exposed to DSS were treated with various doses of Oxo (1, 5, 10 mg/kg body weight). Plasma ALT, GOT, AST, and creatinine levels were examined. Toxicity from Oxo treatment was only observed at and higher than a dose of 10 mg/kg body weight (data not shown). Subsequent experiments with Oxo were conducted at doses of 1 and 5 mg/kg body weight. Mice were treated with Oxo and sacrificed as illustrated in Figure 3A. Our initial studies were focused on acute IBD, while mice were on DSS for 7 days. There was no detectable effect of treatment with vehicle (DMSO + mineral oil) on DSS-induced epithelial degeneration and infiltration of inflammatory cells in the colon mucosa (Fig. 3B). However, treatment with Oxo reduced loss in crypts, epithelial damage, and the infiltration of inflammatory cells in the colon mucosa (Fig. 3B). GC treatment is a mainstay therapy for the acute flares of IBD. We examined whether treatment with dexamethasone (Dex, a synthetic GC) results in additional benefits in Oxo-treated DSS-exposed mice. There was no significant difference in epithelial architecture or immune cell infiltration between Oxo and Oxo+Dex–treated groups. Oxo treatment significantly prevented the loss in body weight (P < 0.05; Fig. 3C) and colon length shortening (P = 0.0004; Fig. 3D) in DSS-exposed mice. Again, treatment with Dex had no additional beneficial effect on above parameters of IBD pathogenesis. The DAI in DSS-exposed mice was reduced by 59% in Oxo (5 mg/kg body weight)-treated mice compared to vehicle-treated mice (Fig. 3E; P = 0.0001). Also, treatment with Oxo prevented histopathological score by 61% (Fig. 3F; P = 0.002) in comparison with the vehicle-treated group. Once again, there was no significant difference between Oxo and Oxo+Dex–treated groups.

The efficacy of Oxo in restricting activation of inflammation-inducing signaling mediators was determined. Substantial increases in the phosphorylation of TAK1, JNK, p38 MAPK, and 1x8z in the colonic tissues were observed in vehicle-treated mice exposed to DSS (Fig. 4A). However, treatment with Oxo markedly reduced phosphorylation of all signaling intermediators investigated in these studies (Fig. 4A). Since proinflammatory cytokines promote intestinal inflammation, effects of TAK1 inhibition on cytokine synthesis were evaluated. Elevated expression of IL-6, TNF-α, and IL-12 were not affected by the treatment with vehicle (Fig. 4B). However, treatment with Oxo significantly inhibited expression of IL-6 (P = 0.0001), TNF-α (P = 0.01), and IL-12 (P = 0.005) induced by DSS exposure (Fig. 4B).

Inhibition of TAK1 enhances recovery from DSS-induced colitis in mouse

Next, we assessed the effect of TAK1 inhibition in recovery from DSS-induced injury and inflammation. Mice were treated and sacrificed as depicted in Fig. 5A. To evaluate the effect of 5 days of DSS exposure on the recovery phase of IBD, mice were monitored for an
additional 14 days. The acute pathogenesis was not resolved after the removal of DSS. Vehicle-treated mice continued to lose body weight even after removal of DSS until day 11, while they started to regain the weight (Fig. 5B). There was no detectable rectal bleeding at days 10–19; however, the disease activity (including diarrhea) and histopathology score remained high (Fig. 5 E and F). The regaining of body weight improved in Oxo-treated mice (Fig. 5B). Significant regaining in body weight in Oxo-treated mice was observed as early as at

---

**Figure 3.** Pharmacological inhibition of TAK1 reduces pathogenesis in DSS-induced acute IBD. (A) Male and female C57BL/6 mice (n = 12–15 per group) were on 3% DSS. Mice were treated with Dex (1 mg/kg body weight) and TAK1 inhibitor Oxo or vehicle (DMSO + mineral oil) (1 or 5 mg/kg) and sacrificed as indicated. (B) H&E stained colon tissues. Magnification: 200×; scale bar: 100 μmol/L. (C) Loss in body weight. Data presented as mean ± SEM. *P < 0.05 versus DSS+vehicle. (D) Colon lengths, (E) Disease activity and (F) Histopathology were determined. All data presented as mean ± SEM.
day 12 ($P < 0.05$). After 2 weeks of DSS withdrawal, there was an 8% increase in body weight in Oxo-treated mice compared to vehicle-treated mice (Fig. 5B; $P < 0.05$). The microscopic progression of DSS-induced colitis at day 19 includes an increase in the infiltration of inflammatory cells into the mucosa and submucosa (Fig. 5C). At day 19, partial regeneration of crypts and reepithelialization were observed; however, still there was a marked damage in colon mucosal architecture (Fig. 5C). Treatment with the vehicle had no beneficial effect on mucosal degeneration. In contrast, treatment with Oxo, especially at a dose of 5 mg/kg body weight, resulted in regeneration of crypts and reepithelialization (Fig. 5C). Also, infiltration of inflammatory cells in the colon mucosa and submucosa was prevented in Oxo-treated mice (Fig. 5C).

In the recovery model of colitis, even after 2 weeks of DSS removal, there was a 22% reduction in colon length ($P = 0.0001$) compared to the experimental group not treated with DSS (Fig. 5D). Treatment with Oxo resulted in a 16% recovery ($P = 0.0005$) in the colon length of DSS-exposed mice (Fig. 5D). Treatment with vehicle had no beneficial effect on DSS-induced disease activity or histopathology in semichronic IBD (Fig. 5D). However, a significant reduction in disease activity ($P = 0.001$) (Fig. 5E) and histopathology scores ($P = 0.001$) were observed in Oxo-treated mice compared to vehicle-treated mice (Fig. 5F). Although less prominent than the acute form of DSS-IBD, elevated levels of proinflammatory cytokines were also detected in the recovery phase (Fig. 5G). Treatment with Oxo significantly inhibited IL-6 ($P = 0.01$), TNF-α ($P = 0.006$) and IL-12 ($P = 0.02$) expression in the colonic tissues compared to the vehicle-treated groups (Fig. 5G). Phosphorylation of TAK1 at the recovery phase of DSS-colitis was markedly reduced in Oxo-treated mice to a level comparable to control mice treated with vehicle only (Fig. 5H).

It is notable that in both acute and recovery phase of DSS-colitis, Oxo treatment facilitated epithelial monolayer integrity and restitution, most likely because of the profound decrease in mucosal proapoptotic cytokine expression. Together, our data suggest that activation of TAK1 is required for driving pathogenesis in DSS-induced IBD.

**Inhibition of TAK1 reduces pathogenesis in NSAID-induced IBD in IL-10−/− mice**

NSAID (Piroxicam)-accelerated IBD in IL-10−/− mice highly resembles human IBD in terms of heterogeneous pathogenesis and impaired epithelial integrity in disease development (Holgersen et al. 2014). To examine whether...
TAK1 Activation in IBD

Z. Liu et al.
activation of TAK1 is a general mechanism in driving the pathogenesis, the role of TAK1 in NSAID/IL-10^{-/−} model of IBD was assessed. Mice were treated with piroxicam (Px) and Oxo (5 mg/kg body weight) as indicated in Figure 6A. Untreated IL-10^{-/−} mice at 6 weeks of age did not exhibit gross colonic inflammation; however, colitis was found in 100% of the IL-10^{-/−} mice treated with Px (data not shown). Similar observations were reported by Berg et al. (2002). Treatment with Px resulted in gradual loss in body weight (Fig. 6B). Treatment with vehicle had no significant effect on Px-induced loss in body weight in IL-10^{-/−} mice. However, Oxo significantly prevented reduction in body weight (P < 0.05; Fig. 6B). After 9 days of Px treatment, moderate loss of crypts and multifocal inflammatory infiltrates were observed in the lamina propria, predominantly in the proximal colon. Epithelial hyperplasia and occasional ulceration were found at the inflammatory lesions. There was no detectable change in microscopic pathogenesis in Px-exposed IL-10^{-/−} mice treated with the vehicle. Notably, treatment with Oxo mitigated restricted infiltration of inflammatory cells and reduced thickening of the muscularis mucosa (Fig. 6C). The loss of crypts and epithelial damage were partially prevented in Oxo-treated IL-10^{-/−} mice. Also, the shortening of colon length in IL-10^{-/−} mice were significantly prevented by Oxo treatment (Fig. 6D; P < 0.05). Moreover, elevated levels of IL-6 and TNF-α expression in IL-10^{-/−} mice were significantly reduced by the treatment with Oxo but not vehicle (Fig. 6E; P < 0.05). Phosphorylation of TAK1 in Px-exposed IL-10^{-/−} mice was substantially prevented by the treatment with Oxo to a level comparable to control mice treated with vehicle only (Fig. 6F). Together, pharmacological inhibition of TAK1 activation was beneficial in different mouse models of IBD.

**Activation of TAK1 in F4/80⁺ macrophages in the recovery phase of DSS-colitis**

Although the immunofluorescent staining in Figure 2E demonstrated nonepithelial expression of activated TAK1 in IL-10^{-/−} model of colitis, the cell type(s) remains to be identified. Among nonepithelial cells, macrophages are considered as the primary responders in IBD. Infiltration of macrophages is elevated in colonic biopsy samples from IBD patients, and produce large amounts of proinflammatory cytokines, chemokines, and retain respiratory burst activity (Murch et al. 1993; Rugtveit et al. 1994, 1995, 1997; Smith et al. 2005; Smythies et al. 2005; Schenk et al. 2007; Kamada et al. 2008). We assessed TAK1 phosphorylation in F4/80⁺ macrophages in DSS-induced semichronic IBD. TAK1⁺ cells (Green) in the colon mucosa were found to be predominantly F4/80⁺ cells (Red), as demonstrated by costaining (Fig. 7). Therefore, at the recovery/semichronic phase of DSS-colitis, majority of TAK1⁺ cells in the colon mucosa were macrophages.

**Discussion**

In this study, we define a new mechanism for the intestinal inflammation. We hypothesized that dysregulated activation of TAK1 facilitates colonic mucosal inflammation and subsequent pathogenesis in IBD. In support of this premise, we find hyper activation of TAK1 in patients with active UC or CD, as well as in murine models of IBD. We provide evidence for substantial reduction in IBD-associated colon mucosal pathogenesis and clinical symptoms in experimental IBD by pharmacological inhibition of TAK1 activity. Further, we demonstrate that GC, a first line of treatment for IBD, fails to restrain activation of TAK1 and subsequent inflammatory reactions in mouse IBD.

The function of TAK1 in IBD is enigmatic and remains to be discerned. Several recent studies indicated association of TAK1 activation with the disease pathogenesis in IBD. In contrast, selective deletion of TAK1 in intestinal epithelial cells demonstrated cytoprotective roles of TAK1 in DSS-colitis. In this study, we demonstrated upregulation in TAK1 phosphorylation in colonic tissue specimens from pediatric patients with UC or CD, indicating elevated TAK1 activation in IBD (Fig. 1). While there are differences between pediatric and adult IBD in terms of the clinical course, the etiology of the disease is thought to be similar (Kelsen and Baldassano 2008). Further, symptoms for pediatric IBD are similar to those observed in adults (McMullin et al. 2014). We anticipate that a similar profile for TAK1 activation would be observed in adult IBD patients. However, additional studies are required to address this. Nevertheless, we found that signaling intermediates downstream of TAK1 activation, such as NFκB, JNK, and p38 MAPK, were also activated in pediatric IBD patients (Fig. 1). These observations were further supported by the upregulation of TAK1, NFκB, JNK, and p38 MAPK activation in two distinct murine models of IBD.

**Figure 5.** Inhibition of TAK1 reduces pathogenesis in the recovery phase of DSS-induced IBD. (A) Male and female C57BL/6 mice (n = 12–15 per group) were on 3% DSS and with vehicle (DMSO+mineral oil) or Oxo (1 or 5 mg/kg body weight) and sacrificed as indicated. (B) Loss in body weight. Data presented as mean ± SEM. *P < 0.05 versus DSS+vehicle. (C) H&E stained colons tissues; magnification: 200×; scale bar: 100 μmol/L. (D) Colon lengths, (E) Disease activity and (F) Histopathology were determined. (B) Expression of IL-6, TNF-α and IL-12 in colon homogenates were analyzed by ELISA. Data presented as mean ± SEM.
TAK1 Activation in IBD

Z. Liu et al.
Together, we find activation of TAK1 as an integral part of human and murine IBD. These results are concordant with a recent study that suggested positive correlation between RKIP (a kinase upstream to TAK1) activation and disease severity in IBD patients, as well as between RKIP and TAK1 phosphorylation in DSS and TNBS models of colitis (Lin et al. 2016). Our immunofluorescence studies indicated elevated p-TAK1 expression, prominently in nonepithelial cells (Fig. 2 E and F). Here, we used epithelial injury/repair model (DSS-colitis) and epithelial injury/adaptive immune hyperactive model (NSAID/IL-10−/−) of human IBD, which exhibit predominant proinflammatory roles and involve innate immune cells including neutrophils and macrophages. It is plausible that during intestinal inflammation, TAK1 exerts cell-specific distinct functions. For example, TAK1 in intestinal epithelial cells maintains mucosal homeostasis, while TAK1 in innate immune cells promotes mucosal inflammation and subsequent pathogenesis. In support of this premise, MyD88, a TLR-adapter protein pivotal for TAK1 activation, has pathogenic and protective roles in leukocytes and epithelial cells, respectively, in mouse IBD (Jobin 2010; Muhlbauer et al. 2013). Beneficial and detrimental roles of NFκB in intestinal homeostasis and diseases have been demonstrated previously (Karrasch and Jobin 2008). Moreover, TNF, a TAK1-activating ligand, has both protective and pathophysiological roles in IBD (Edelblum et al. 2008; Dube et al. 2015; Punit et al. 2015).

To date, there is no direct evidence for functional roles of TAK1 in facilitating inflammation and associated...
pathogenesis in IBD. Here, we performed a comprehensive study to determine whether TAK1 is dispensable in coordinating colon mucosal inflammation. To examine the therapeutic benefit of TAK1 inactivation, mice were treated with Oxo, a highly selective pharmacological inhibitor of TAK1 following the exposure to DSS. At first, we investigated the effects of Oxo on DSS-induced acute IBD. Treatment with Oxo at a dose of 1 or 5 mg/kg body weight alleviated the clinical symptoms and micro/macroscopic pathogenesis in acute IBD (Fig. 3). Consistently, Oxo restrained activation of TAK1 and the downstream signaling intermediates that contribute to inflammatory reactions including synthesis of proinflammatory cytokines (Fig. 4). These results suggest that the suppression of TAK1 activation ameliorate pathogenesis in DSS-induced acute IBD. However, at a dose of 10 mg/kg body weight or higher, Oxo exhibited some toxicity in DSS-treated mice. Since TAK1 is required for several cellular functions, it is plausible that complete inhibition of TAK1 activity at relatively high doses of Oxo might have interfered with physiological homeostasis and thereby introduced toxicity. Nevertheless, inhibition of TAK1 activity was indeed beneficial in acute IBD.

A limitation of experimental IBD is the unavailability of a single-animal model that represents all major characteristics of human IBD. IL-10−/− mice develop IBD spontaneously. The disease phenotypes and histopathology in IL-10−/− mice are grossly different from DSS-colitis, especially for the heterogeneous intestinal pathogenesis that resembles CD (Holgersen et al. 2014). To examine the generality of TAK1 activation as an important mechanism for IBD, we investigated the effect of TAK1 inhibition on colon mucosal pathogenesis in IL-10−/− mice. To synchronize the onset and accelerate the development of IBD, IL-10−/− mice were administered piroxicam/NSAID in chow (Berg et al. 2002). Like DSS-induced acute IBD, pharmacological inhibition of TAK1 exhibited profound recovery in IL-10−/− mice from piroxicam-mediated colon mucosal pathogenesis. These results implicated elevated activation of TAK1 as a common mechanism for intestinal inflammation.

Since IBD is a chronic inflammatory condition of the gastrointestinal tract, we extended our studies to investigate the roles of TAK1 in the recovery phase of DSS-induced IBD. This model was established by Melgar et al. (2005) and later successfully reproduced by several independent studies (Sha et al. 2013). At the recovery phase of the disease, we observed moderate-to-low activation of TAK1, JNK, and p38 MAPK compared to acute DSS-induced IBD (Fig. 2B). Also, the expression levels of TNF-α and IL-6, the hallmarks of intestinal inflammation were lower in the recovery phase compared to acute IBD (Figs. 4B and 5G). Nonetheless, activation of TAK1 and the downstream signaling mediators as well as the proinflammatory signatures were still substantially higher than the control/untreated mice. Consistent with these observations, persistent loss in body weight, disease activity, shortening in colon length, and microscopic histopathology were found till the end-point (19 days) of the study, while DSS was withdrawn after 5 days of treatment (Fig. 5). In the recovery model of IBD, we treated mice with Oxo after 4 days of DSS withdrawal, the transition period from acute to semichronic IBD. Pharmacological inhibition of TAK1 prevented most of the above pathogenesis in the recovery phase, at least in part. However, the beneficial effects of Oxo in maintaining colon mucosal architecture and restraining inflammatory infiltrates were more pronounced in the acute phase compared to recovery phase of the disease. It is likely that TAK1 activation, which promotes intestinal inflammation predominantly occurs at the acute stage. However, the residual TAK1 activation that persisted in the recovery phase was also suppressed by Oxo. Hence, inhibition of TAK1 activity was beneficial for the recovery phase as well as the acute stage of the disease. Our data suggest uncontrolled activation of TAK1 may account for the inflammation-related pathologies in IBD. GC therapies are the standard treatment for moderate-to-severe IBD as they facilitate rapid remission of disease activity. However, there was no additional beneficial effect from GC treatment while mice were treated with both Oxo and Dex (Fig. 3).

Notably, we find suppression of TAK1 activation is beneficial in colitis, while previous reports suggest protective roles of epithelial TAK1 (Kajino-Sakamoto et al. 2008; Kim et al. 2009). Cell-specific roles of signaling mediators and inflammatory agents in inflammatory bowel disease are an emerging field of research. MyD88, a TLR-adapter protein pivotal for TAK1 activation, has pathogenic and protective roles in leukocytes and epithelial cells, respectively, in mouse IBD (Jobin 2010; Muhlbaier et al. 2013). Moreover, TNF, a TAK1 activating ligand, has both protective and pathophysiological roles in IBD (Edelblum et al. 2008; Dube et al. 2015; Punit et al. 2015). Intriguingly, at the early stage of the disease (after 3 days of DSS treatment), the activation of TAK1 is restricted in the epithelial cells, while TAK1 activation in the nonepithelial cells is negligible. We posit that epithelial TAK1 contributes less at the advanced stage of the disease and Oxo-dependent suppression of colonic inflammation is primarily mediated via inhibition of TAK1 activation in the nonepithelial immune cells in the lamina propria. In support of this premise, costaining studies suggest that TAK1 phosphorylation predominantly occurs in macrophages (Fig. 7). Additional studies involving mice with conditional deletion of TAK1 in macrophages are required to ascertain the roles of macrophage-derived TAK1 in IBD.
Collectively, we demonstrate activation of TAK1 as a critical mechanism for colon mucosal inflammation. Targeting inflammation-inducing cell signaling mediators has been an active area for new drug discovery in IBD. TAK1 is upstream of many inflammatory pathways, such as MAPK and JAK-STAT, currently targeted in IBD (Van Den Blink et al. 2002; Bamias et al. 2016). Therefore, a major consequence of targeting TAK1 would be higher anti-inflammatory efficacy by concomitant suppression of many pathways. One attractive mechanism, then, by which inflammatory outcomes in IBD could be prevented is through pharmacological inhibition of TAK1 action. A limitation of this approach would be the collateral suppression of TAK1 activity in intestinal epithelial cells that is required for colon mucosal homeostasis. Future studies on mucosal cell-specific TAK1 activation would be a prelude for cell-restricted TAK1 inhibition as an alternative strategy to treat IBD.

Acknowledgments

SB would like to thank professor Louis J. Muglia for manuscript review and valuable discussions. SB would also like to thank Dr. Lin Fei for statistical assistance.

Conflict of Interest

No conflicts of interest, financial or otherwise, are declared by the authors.

Reference

Abbott, D. W., Y. Yang, J. E. Hutti, S. Madhavarapu, M. A. Kelliher, and L. C. Cantley. 2007. Coordinated regulation of Toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains. Mol. Cell. Biol. 27:6012–6025.

Aceituno, M., E. Garcia-Planella, C. Heredia, Y. Zabana, F. Feu, E. Domenech, et al. 2008. Steroid-refractory ulcerative colitis: Predictive factors of response to cyclosporine and validation in an independent cohort. Inflamm. Bowel Dis. 14:347–352.

Adhikari, A., M. Xu, and Z. J. Chen. 2007. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 26:3214–3226.

Bamias, G., T. T. Pizarro, and F. Cominelli. 2016. Pathway-based approaches to the treatment of inflammatory bowel disease. Transl. Res. 167:104–115.

Berg, D. J., J. Zhang, J. V. Weinstock, H. F. Ismail, K. A. Earle, H. Allila, et al. 2002. Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology 123:1527–1542.

Bhattacharyya, S., C. K. Ratajczak, S. K. Vogt, C. Kelley, M. Colonna, R. D. Schreiber, et al. 2010. TAK1 targeting by glucocorticoids determines JNK and IkappaB regulation in Toll-like receptor-stimulated macrophages. Blood 115:1921–1931.

Boyle, M. P., J. A. Brewer, M. Funatsu, D. F. Wozniak, J. Z. Tsien, Y. Izumi, et al. 2005. Acquired deficit of forebrain glucocorticoid receptor produces depression-like changes in adrenal axis regulation and behavior. Proc. Natl Acad. Sci. USA 102:473–478.

Colombel, J. F., W. J. Sandborn, W Reinisch, G. J. Mantzaris, A. Kornbluth, S. Lichtiger, et al. . 2010. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N. Engl. J. Med. 362:1383–1395.

Colombel, J. F., P. Rutgeerts, W. Reinisch, D. Esser, Y. Wang, Y. Lang, et al. 2011. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 141:1194–1201.

Cooper, H. S., S. N. Murthy, R. S. Shah, and D. J. Sedergran. 1993. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 69:238–249.

Dube, P. E., S. Punit, and D. B. Polk. 2015. Redeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel disease. Am. J. Physiol. Gastrointest. Liver Physiol. 308:G161–G170.

Edelblum, K. L., J. A. Goettel, T. Koyama, S. J. McElroy, F. Yan, and D. B. Polk. 2008. TNFR1 promotes tumor necrosis factor-mediated mouse colon epithelial cell survival through RAF activation of NF-kappaB. J. Biol. Chem. 283:29485–29494.

Grillo, A. R., M. Scarpa, R. D’Inca, P. Brun, M. Scarpa, A. Porzionato, et al. 2015. TAK1 is a key modulator of the profibrogenic phenotype of human ileal myofibroblasts in Crohn’s disease. Am. J. Physiol. Gastrointest. Liver Physiol. 309:G443–G454.

Holgersen, K., P. H. Kvist, H. Markholst, A. K. Hansen, and T. L. Holm. 2014. Characterisation of enterocolitis in the piroxicam-accelerated interleukin-10 knock out mouse—a model mimicking inflammatory bowel disease. J. Crohns. Colitis 8:147–160.

Jobin, C. 2010. MyD88 signaling in the intestine: Dr Jekyll and Mr Hyde? Gastroenterology 139:383–385.

Kajino-Sakamoto, R., M. Inagaki, E. Lippert, S. Akira, S. Robine, K. Matsumoto, et al. 2008. Enterocyte-derived TAK1 signaling prevents epithelium apoptosis and the development of ileitis and colitis. J. Immunol. 181:1143–1152.

Kamada, N., T. Hisamatsu, S. Okamoto, H. Chinen, T. Kobayashi, T. Sato, et al. 2008. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J. Clin. Invest. 118:2269–2280.

Karrasch, T., and C. Jobin. 2008. NF-kappaB and the intestine: friend or foe? Inflamm. Bowel Dis. 14:114–124.

Kawachi, S., S. Jennings, J. Panes, A. Cockrell, F. S. Laroux, L. Gray, et al. 2000. Cytokine and endothelial cell adhesion molecule expression in interleukin-10-deficient mice. Am. J. Physiol. Gastrointest. Liver Physiol. 278:G734–G743.
Kelsen, J., and R. N. Baldassano. 2008. Inflammatory bowel disease: the difference between children and adults. Inflamm. Bowel Dis. 14(Suppl 2):S9–S11.

Kim, J. Y., R. Kajino-Sakamoto, E. Omori, C. Jobin, and J. Ninomiya-Tsuji. 2009. Intestinal epithelial-derived TAK1 signaling is essential for cytoprotection against chemical-induced colitis. PLoS ONE 4:e4561.

Kong, F., G. Laryea, Z. Liu, and S. Bhattacharyya. 2015. Raf kinase inhibitor protein mediates intestinal epithelial cell apoptosis and promotes IBDs in humans and mice. Gut doi: 10.1136/gutjnl-2015-310096.

Lim, S. M., J. J. Jeong, G. D. Kang, K. A. Kim, H. S. Choi, and D. H. Kim. 2015. Timosaponin AIII and its metabolite sarsasapogenin ameliorate colitis in mice by inhibiting NF-kappaB and MAPK activation and restoring Th17/Treg cell balance. Int. Immunopharmacol. 25:493–503.

Lin, W., C. Ma, F. Su, Y. Jiang, R. Lai, T. Zhang, et al. 2016. RaF kinase inhibitor protein mediates intestinal epithelial cell apoptosis and promotes IBDs in humans and mice. Gastroenterology 149:986–994.

Ma, F. Y., G. H. Tesch, E. Ozols, M. Xie, M. D. Schneider, and D. J. Nikolic-Paterson. 2011. TGF-beta1-activated kinase 1 regulates inflammation and fibrosis in the obstructed kidney. Am. J. Physiol. Renal. Physiol. 300: F1410–F1421.

McMullin, C. M., J. Morton, S. Vickramarajah, E. Cameron, M. Parkes, F. Torrente, et al. 2014. A comparison of outcomes for adults and children undergoing resection for inflammatory bowel disease: is there a difference? IRSN Gastroenterol. 2014:410753.

Melgar, S., A. Karlsson, and E. Michaelsson. 2005. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 288:G1328–G1338.

Mehl, D., Q. Xia, G. Paradiso, J. Ling, T. Moccia, C. Carbone, et al. 2011. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J. Natl Cancer Inst. 103:1190–1204.

Muhlauer, M., E. Perez-Chanona, and C. Jobin. 2013. Epithelial cell-specific MyD88 signaling mediates ischemia/reperfusion-induced intestinal injury independent of microbial status. Inflamm. Bowel Dis. 19:2857–2866.

Murch, S. H., C. P. Braegger, J. A. Walker-Smith, and T. T. MacDonald. 1993. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34:1705–1709.

Neubert, M., D. A. Ridder, P. Bargiotas, S. Akira, and M. Schwaninger. 2011. Acute inhibition of TAK1 protects against neuronal death in cerebral ischemia. Cell Death Differ. 18:1521–1530.

Ninomiya-Tsuji, J., T. Kajino, K. Ono, O. Tohtomo, M. Matsumoto, N. Shinya, et al. 2003. A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase. J. Biol. Chem. 278:18485–18490.

Obermeier, F., G. Kojojharoff, W. Hans, J. Scholmerich, V. Gross, and W. Falk. 1999. Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin. Exp. Immunol. 116:238–245.

Okayasu, I., S. Hatakeyama, M. Yamada, T. Ohkusa, Y. Inagaki, and R. Nakaya. 1990. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98:694–702.

Punth, S., P. E. Dube, C. Y. Liu, N. Girish, M. K. Washington, and D. B. Polk. 2015. Tumor Necrosis Factor Receptor 2 Restricts the Pathogenicity of CD8(+) T Cells in Mice With Colitis. Gastroenterology 149:993–1005.e1002.

Reiley, W. W., W. Jin, A. J. Lee, A. Wright, X. Wu, E. F. Tewalt, et al. 2007. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J. Exp. Med. 204:1475–1485.

Ridder, D. A., and M. Schwaninger. 2012. TAK1 inhibition for treatment of cerebral ischemia. Exp. Neurol. 239C:68–72.

Ridder, D. A., M. F. Lang, S. Salinin, J. P. Roderer, M. Struss, C. Maser-Gluth, et al. 2011. TAK1 in brain endothelial cells mediates fever and lethargy. J. Exp. Med. 208:2615–2623.

Rosen, M. J., A. Dhawan, and S. A. Saeed. 2015. Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 169:1053–1060.

Rugtveit, J., P. Brandtzæg, T. S. Halstensen, O. Fausa, and H. Scott. 1994. Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut 35:669–674.

Rugtveit, J., G. Haraldsen, A. K. Hogasen, A. Bakka, P. Brandtzæg, and H. Scott. 1995. Respiratory burst of intestinal macrophages in inflammatory bowel disease is mainly caused by CD14 + L1 + monocyte derived cells. Gut 37:367–373.

Rugtveit, J., E. M. Nilsen, A. Bakka, H. Carlsen, P. Brandtzæg, and H. Scott. 1997. Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from
inflammatory bowel disease. Gastroenterology 112:1493–1505.
Sakurai, H. 2012. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol. Sci. 33:522–530.
Sanjo, H., S. Tokumaru, S. Akira, and S. Taki. 2015. Conditional deletion of TAK1 in T cells reveals a pivotal role of TCRalphabeta+ intraepithelial lymphocytes in preventing lymphopenia-associated colitis. PLoS ONE 10: e0128761.
Sato, S., H. Sanjo, T. Tsujimura, J. Ninomiya-Tsuji, M. Yamamoto, T. Kawai, et al. 2006. TAK1 is indispensable for development of T cells and prevention of colitis by the generation of regulatory T cells. Int. Immunol. 18:1405–1411.
Schenk, M., A. Bouchon, F. Seibold, and C. Mueller. 2007. TREM-1–expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J. Clin. Invest. 117:3097–3106.
Sha, T., K. Igaki, M. Yamasaki, T. Watanabe, and N. Tsuchimori. 2013. Establishment and validation of a new semi-chronic dextran sulfate sodium-induced model of colitis in mice. Int. Immunopharmacol. 15:23–29.
Simmons, A. N., R. Kajino-Sakamoto, and J. Ninomiya-Tsuji. 2016. TAK1 regulates Paneth cell integrity partly through blocking necroptosis. Cell Death Dis. 7:e2196.
Singh, A., M. F. Sweeney, M. Yu, A. Burger, P. Greninger, C. Benes, et al. 2012. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 148:639–650.
Smith, P. D., C. Ochsenbauer-Jambor, and L. E. Smythies. 2005. Intestinal macrophages: unique effector cells of the innate immune system. Immunol. Rev. 206:149–159.
Smythies, L. E., M. Sellers, R. H. Clements, M. Mosteller-Barnum, G. Meng, W. H. Benjamin, et al. 2005. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J. Clin. Invest. 115:66–75.
Takahashi, H., C. Jin, H. Rajabi, S. Pitroda, M. Alam, R. Ahmad, et al. 2015. MUC1-C activates the TAK1 inflammatory pathway in colon cancer. Oncogene 34:5187–5197.
Van Den Blink, B., T. Ten Hove, G. R. Van Den Brink, M. P. Peppelenbosch, and S. J. Van Deventer. 2002. From extracellular to intracellular targets, inhibiting MAP kinases in treatment of Crohn’s disease. Ann. N. Y. Acad. Sci. 973:349–358.
Winssinger, N., and S. Barluenga. 2007. Chemistry and biology of resorcylic acid lactones. Chem. Commun. (Camb.) 22–36.
Xavier, R. J., and D. K. Podolsky. 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448:427–434.